The NICE has issued final draft guidance endorsing the use of CSL Vifor's Filspari (sparsentan) for primary IgA nephropathy.

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

Aptar Digital Health has signed a licensing agreement with AstraZeneca for detecting CKD using the latter’s AI-driven ...

In combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and anti-oestrogen drug Faslodex (fulvestrant), Itovebi ...

An ATS 2025 session presented data showing that anti–IL-5 biologics significantly cut exacerbations in coexisting asthma and ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Eli Lilly and Company has received marketing authorisation from the Australian Therapeutic Goods Administration (TGA) for ...

The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their ...

The Trump administration’s budget reconciliation bill has passed the US House of Representatives by a wafer-thin single-vote ...

Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered ...

Orionis Biosciences has announced a multi-year partnership with Roche’s Genentech for small-molecule monovalent glue medicine ...